

Change Notification for the UK Blood Transfusion Services

Date of Issue: 17 May 2024

Implementation: to be determined by each Service

No. 29 – 2024

Revised component specification:

Human Plasma for Fractionation, Leucocyte Depleted

This notification includes the following changes:


BM-DSG	CB-DSG	GDRI	TD-DSG	TL-DSG	WB-DSG	Red Book
Bone Marrow & Peripheral Blood Stem Cell	Cord Blood	Geographical Disease Risk Index	Tissue – Deceased Donors	Tissue – Live Donors	Whole Blood & Components	Guidelines for the BTS in the UK

1. Chapter 7.5.6



Ryan Evans

Chair of Standing Advisory Committee on Blood Components (SACBC)



Dr Stephen Thomas

Professional Director of JPAC

Changes are indicated using the key below. This formatting will not appear in the final entry.

original text

«inserted text»

~~deleted text~~

1. Changes apply to the **Red Book**

Chapter 7: Specifications for blood components

7.5.6: Human Plasma for Fractionation, Leucocyte Depleted

Plasma that has been obtained from whole blood or by apheresis (as defined in section 7.1.4), containing less than 1×10^6 leucocytes per unit.

UK derived plasma may be used for the manufacture of immunoglobulins «and albumin» for domestic use provided all relevant vCJD risk mitigation measures currently in place for blood components for transfusion are applied and manufacturers submit an application to the MHRA to register the use of UK-sourced plasma including a product specific risk assessment. Manufacture of other blood products such as clotting factors ~~or albumin~~ is not currently permitted.

(no further changes to 7.5.6)